ASTRO Annual Meeting
MIAMI - Combination low-dose rate brachytherapy and external beam
radiation treatment yielded excellent outcomes in patients with intermediate-
and high-risk prostate cancer.
Eyud Abu-Isa, MD, and colleagues from the University of Michigan
Medical Center evaluated the outcomes of the combination treatment in 159
intermediate-risk patients and 118 high-risk patients who were treated from
1995 to 2008. The median follow-up was 3.4 years for biochemical control and
5.5 years for survival.
The median planned implant dose was 90 Gy and the median external beam
radiation treatment pelvic dose was 45 Gy. Androgen deprivation therapy was
used in 36% of the intermediate-risk patients for a median of 4 months, and 88%
of the high-risk patients for a median of 12 months. Patient-reported outcomes
of genitourinary symptoms, gastrointestinal symptoms and sexual function were
measured in 85% of patients at baseline and follow-up. The researchers analyzed
freedom from biochemical failure, freedom from metastasis and cause-specific
Patients with intermediate-risk disease had a 94% rate of freedom from
biochemical failure, 98% rate of freedom from metastasis and a 100% rate of
survival. Patients with high-risk disease had a 75% rate of freedom from
biochemical failure, an 87% rate of freedom from metastasis and a 90% rate of
survival. In high-risk patients with a PSA <20, the freedom from biochemical
failure rate was 88%, the freedom from metastasis rate was 91% and the survival
rate was 95%.
After a 4-year follow-up, the mean AUA score was 5.8, the mean rate of
dysuria episodes was 0.57 and the mean rectal distress score was 0.35. In men
who had no or minimal erectile dysfunction at baseline, the potency
preservation was 58% in those without prior ADT and 57% in those with prior
For more information:
- Abu-Isa EI. #2396. Presented at: the 2011 ASTRO Annual Meeting;
Oct. 2-6, 2011; Miami.
Disclosure: The researchers report no relevant financial disclosures.